AbolerIS Pharma
Carole Guillonneau is an accomplished researcher and co-founder of AbolerIS Pharma, serving as Head of Research since November 2019. Carole is also the Director of the FOCIS Center of Excellence at Nantes University, a role held since June 2022. In addition, Carole has been a Director of Research at the CNRS since October 2017, leading teams focused on cell and gene engineering in immunology and regenerative medicine. Prior experience includes roles as Chargé de Recherche at CNRS from 2009 to 2017 and a post-doctorate at Melbourne University. Carole holds a PhD in Immunology from Université Paris Cité and has completed the Entrepreneurs in Clinical Academia program at INSEAD. Additionally, Carole serves as an Associate Editor for the journal Transplantation.
This person is not in the org chart
AbolerIS Pharma
AbolerIS Pharma will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases. Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells. IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells. Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.